While early 2023 saw COVID-19 finally fading away, other global crises continued throughout the year (Russia-Ukraine invasion) or were newly created (Israel-Hamas conflict). In short, the socioeconomic environment remained turbulent.
Also, high interest rates continued to trouble biotech companies and their investors, as reflected in the XBI being down 6%...